Want to see FHTX full AI Analyst Report?
Top Page
Foghorn Therapeutics
(NASDAQ:FHTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-70.10% Downside)
Action:Reiterated
Date:10/03/26
The score is held down primarily by weak financial performance—large ongoing losses, negative equity, and significant cash burn—combined with very bearish technicals (price well below major moving averages and negative momentum). Valuation provides limited support due to losses (negative P/E) and no dividend, while corporate events are mixed: a discontinued collaboration program is a setback, partially offset by cost cuts aimed at extending runway.
Positive Factors
Proprietary drug-discovery platform
Foghorn’s proprietary chromatin-regulatory platform provides a differentiated foundation for discovering genetically defined cancer therapies. Its focus on selective degraders and induced-proximity approaches could support multiple programs, allowing platform value to extend beyond any single clinical candidate over the next several quarters.
Negative Factors
Persistent losses and cash burn
Large recurring losses and substantial operating cash outflows show that Foghorn’s development model currently consumes capital faster than it generates sustainable earnings. Continued burn can force additional financing or program prioritization, potentially limiting flexibility and creating dilution or funding risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug-discovery platform
Foghorn’s proprietary chromatin-regulatory platform provides a differentiated foundation for discovering genetically defined cancer therapies. Its focus on selective degraders and induced-proximity approaches could support multiple programs, allowing platform value to extend beyond any single clinical candidate over the next several quarters.
Read all positive factors
Foghorn Therapeutics (FHTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$121.74M
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue Growth51.98%
EPS Growth17.68%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.99
Shares Outstanding59,385,315
10 Day Avg. Volume644,336
30 Day Avg. Volume1,117,891
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue5.99
Enterprise Value/Gross Profit14.03
Enterprise Value/Ebitda-3.53
Forecast
1Y Price Target
$5.00Price Target Upside-25.26% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$28.72M
Foghorn Therapeutics Business Overview & Revenue Model
Company Description
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company empl...
How the Company Makes Money
Foghorn Therapeutics does not primarily generate revenue from commercial product sales because it is a clinical-stage company and, to the extent publicly disclosed, has no approved products on the market. Its revenue, when reported, is primarily d...
Foghorn Therapeutics Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.74M | 30.91M | 22.60M | 34.16M | 19.23M | 1.32M |
| Gross Profit | 15.70M | 27.58M | 22.60M | 34.16M | 19.23M | 1.32M |
| EBITDA | -62.46M | -70.95M | -97.17M | -90.75M | -105.56M | -96.19M |
| Net Income | -64.58M | -74.28M | -86.62M | -98.43M | -108.88M | -101.32M |
Balance Sheet | ||||||
| Total Assets | 203.39M | 198.10M | 283.98M | 285.92M | 404.88M | 519.77M |
| Cash, Cash Equivalents and Short-Term Investments | 167.58M | 158.89M | 243.75M | 234.06M | 345.80M | 154.29M |
| Total Debt | 43.10M | 41.27M | 37.13M | 45.07M | 51.51M | 58.33M |
| Total Liabilities | 284.43M | 306.60M | 329.51M | 363.11M | 404.77M | 422.90M |
| Stockholders Equity | -81.04M | -108.50M | -45.53M | -77.19M | 112.00K | 96.87M |
Cash Flow | ||||||
| Free Cash Flow | -85.35M | -86.15M | -101.31M | -119.33M | 192.40M | -53.56M |
| Operating Cash Flow | -85.30M | -86.10M | -100.41M | -118.11M | 193.61M | -50.25M |
| Investing Cash Flow | 28.12M | 112.04M | -29.90M | 144.45M | -244.32M | 36.17M |
| Financing Cash Flow | 608.00K | 1.02M | 105.43M | 1.78M | 1.76M | 22.42M |
Foghorn Therapeutics Technical Analysis
Negative
6.69
Price Trends
3.99
Negative
4.47
Negative
4.79
Negative
Market Momentum
-0.53
Negative
27.23
Positive
73.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FHTX, the sentiment is Negative. The current price of 6.69 is above the 20-day moving average (MA) of 2.17, above the 50-day MA of 3.99, and above the 200-day MA of 4.79, indicating a bearish trend. The MACD of -0.53 indicates Negative momentum. The RSI at 27.23 is Positive, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FHTX.
Foghorn Therapeutics Risk Analysis
Foghorn Therapeutics disclosed 54 risk factors in its most recent earnings report. Foghorn Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Foghorn Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $277.72M | -3.01 | -28.54% | ― | ― | 0.04% | |
47 Neutral | $366.61M | -2.98 | -45.45% | ― | 2.33% | 36.86% | |
46 Neutral | $195.97M | -0.84 | -87.95% | ― | -100.00% | 14.08% | |
42 Neutral | $121.74M | -2.07 | 72.64% | ― | 51.98% | 17.68% | |
42 Neutral | $10.93M | -0.02 | 77.63% | ― | 6.81% | 11.95% | |
41 Neutral | $156.25M | -1.00 | -90.30% | ― | ― | 48.20% |
* Healthcare Sector Average
FHTX
Foghorn Therapeutics
2.05
-2.07
-50.24%
KPTI
Karyopharm Therapeutics
0.48
-5.94
-92.49%
FULC
Fulcrum Therapeutics
3.64
-6.01
-62.28%
ZNTL
Zentalis Pharmaceuticals
2.07
0.35
20.35%
ALXO
ALX Oncology Holdings
1.13
-0.57
-33.53%
CCCC
C4 Therapeutics
2.98
0.33
12.45%
Foghorn Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Foghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs
Negative
Oct 1, 2026
On September 25, 2026, Foghorn Therapeutics and Eli Lilly decided not to advance FHD-909, a Phase 1 SMARCA2-targeting program, into the expansion phase and ended further collaboration activities, after the SMARCA2/4 synthetic lethality strategy fa...
Business Operations and StrategyFinancial Disclosures
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress
Positive
Aug 6, 2026
On August 6, 2026, Foghorn Therapeutics reported second-quarter 2026 results and a corporate update, highlighting progress across its oncology and immunology pipeline and collaboration with Eli Lilly. The company’s Phase 1 trial of SMARCA2 i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.